Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol plasma concentration to suppress intubation reaction with ED95 rocuronium in head and neck hyperextension
ChiCTR2500095569Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of propofol in thyroid cancer and parathyroid anomaly, sponsored by Army Medical University. Primary endpoints: Tracheal intubation reaction and Propofol EC50 and EC95 for suppression of intubation reaction. Started Jan 2025; status: recruiting.
02
Drugs
propofol
03
Conditions
thyroid cancerparathyroid anomaly
Beyond the preview
Go deeper on ChiCTR2500095569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095569.